Guggenheim Maintains Buy on Praxis Precision Medicine, Raises Price Target to $1050

Benzinga · 2d ago
Guggenheim analyst Yatin Suneja maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $800 to $1050.